The role of the type 1 transmembrane glycoprotein B7-H3 is controversial in tumorigenesis; thus, a better clarification of its involvement in cancer is crucial. In the present study, 79.3% of cervical cancer samples were found to be B7-H3 positive and the expression of B7-H3 was positively correlated with the clinical features of the samples. Silencing B7-H3 using small interfering RNA or blocking it with intracellular ScFv attenuated the malignancy of HeLa cells. By pull-down assay and liquid chromatography-mass spectrometry in HeLa cells, the glycolytic enzyme ENO1 was found to interact with B7-H3. Subsequently, the involvement of B7-H3 in glycolysis was investigated. We observed decreases in the levels of ATP and lactate, as well as c-Myc and lactate dehydrogenase A, upon B7-H3 downregulation in HeLa cells. The results of the present study provide evidence for B7-H3 mediating tumor glycolysis.
B7-H3, a type I transmembrane glycoprotein, belongs to the immunoglobulin superfamily. Besides being located in the cell membrane, B7-H3 has a wide distribution, including in the cytoplasm and nucleus [1, 2] . Initially, Chapoval et al. [3] reported that B7-H3 could activate the immune system by promoting the proliferation of CD4 + /CD8
+ and upregulating the expression of interferon-c when cloned from the cDNA library of dendritic cells. However, some initial studies provided conflicting information about whether B7-H3 was a co-stimulatory or co-inhibitory molecule [4, 5] . However, further in-depth investigations lead to the consideration that the pro-tumor role of B7-H3 may outweigh its anti-tumor effect because an increasing number studies have confirmed that B7-H3 may function as an oncogene in tumorigenesis [2, 6] . Accordingly, several types of antibody targeted B7-H3, including blocking mAbs, bispecific mAbs and chimeric antigen receptor T cells, have already been constructed and show positive anti-tumor effects [7] .
Notably, recent research has demonstrated that is B7-H3 involved in the metabolism of cancer cells. It was reported that silencing B7-H3 could inhibit tumor glycolysis via the phosphatidylinositol-4,5-bisphosphate Abbreviations ANOVA, analysis of variance; CCT, cervical cancer tissue; DMEM, Dulbecco's modified Eagle's medium; IHC, immunohistochemistry; LC-MS, liquid chromatography-mass spectrometry; LDHA, lactate dehydrogenase A; NC, negative control; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; RLU, relative light unit; siRNA, small interfering RNA; shRNA, small hairpin RNA; VH variable heavy; VL, variable light; WT, wild-type.
3-kinase (PI3K)/Akt/mammalian target of rapamycin pathway [8] . Additionally, another study showed that upregulation of B7-H3 enhances the Warburg effect in tumors by increasing levels of hypoxia-inducible factor1a, lactate dehydrogenase A (LDHA) and phosphoinositide-dependent kinase 1 [9] . Taken together, the function of B7-H3 in tumor glycolysis is worthy of exploration.
ENO1, an important rate-limiting enzyme in glycolysis, is mainly located in the cell membrane and cytoplasm. It catalyzes the formation of phosphoenolpyruvate and produces ATP and, in addition, participates in many physiological processes such as growth regulation and hypoxic endurance [10] .
The primary role of ENO1 in tumor cells is to promote the Warburg effect. Zhan et al. [11] found that the decreased expression of ENO1 via FBXW7-mediated ubiquitination protein degradation pathway impaired the ability of tumor glycolysis and reduced the level of lactate. Moreover, some studies indicated that the alteration of glycolysis regulated by ENO1 contributed to tumor malignancy [12] . A recent study provided evidence to suggest that silencing ENO1 in endometrial cancer cells could inactivate the PI3K/Akt pathways to attenuate the glycolysis, consequently inhibiting cell proliferation and epithelial-mesenchymal transition [12] .
Based on previous studies and technologies, targeted-B7-H3 small hairpin RNA (shRNA) and intracellular anti-B7-H3 ScFv were constructed to inhibit B7-H3 at the expression and function levels in HeLa cells. Subsequently, the abilities of proliferation, clone formation, migration and invasion were investigated with these two cell models, with the aim of better understanding the mechanism of B7-H3 in tumorigenesis, A pull-down assay and liquid chromatography-mass spectrometry (LC-MS) were performed on HeLa cells and ENO1 was identified as the potential protein directly interacting with B7-H3. Furthermore, the expression and activity of ENO1 were examined on these cell models. Moreover, levels of lactate and ATP, as well as the expression of genes related to glycolysis, c-myc and LDHA, were investigated to determine the relationship between B7-H3 and glycolysis. The experimental results obtained should illuminate a new mechanism of B7-H3 with respect to tumor glycolysis, and further lay a solid experimental foundation for developing B7-H3 as a valuable and effective target for cervical cancer therapy.
Materials and methods

Tissue samples and immunohistochemistry (IHC)
Tissue arrays were purchased from Alenabio Biological Technology (Xian, China), including 58 paraffn-embedded cervical cancer tissue (CCT) specimens and 16 normal cervical tissues (CR501a and CR244). IHC was performed on the tissue specimens. First, the samples were dewaxed and treated with hydrogen peroxide. Then, tissues arrays were incubated with rabbit anti-human B7-H3 monoclonal antibody (dilution 1 : 200; Cell Signaling Technology, Danvers, MA, USA) overnight at 4°C. After washing three times with 0.01 M PBS, samples were incubated with goat antirabbit IgG coupled to horseradish peroxidase (ZSBG Biological Technology, Beijing, China) for 45 min at 37°C. The tissue arrays were stained using 2,4-diaminobutyric acid (ZSBG Biological Technology) for 8 min. The result of IHC was evaluated using a semiquantitative system to distinguish different expression levels of B7-H3.
Cell culture
The human cervical cancer cell lines (I.E. HeLa cells) were purchased from the American Type Culture Collection (American Type Culture Collection, Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco, Grand Island, NY, USA) containing 10% FBS (Every Green, Hangzhou, China). The hybridoma cells secreting antibody against B7-H3 were previously developed in our laboratory and were maintained in 1640 medium (Gibco) with 20% FBS. All the cells were incubated at 37°C with 5% CO 2 .
RNA interference vector construction and cell transfection
Targeted-B7-H3 small interfering RNA (siRNA) and negative control (NC) were synthesized by Genepharma (Shanghai, China; see Table S1 ). Accordingly, RNA interference vectors were constructed by inserting the annealing singlestranded oligonucleotides into pSilencer4.1-CMV/neo vector (Ambion, Austin, TX, USA) between the BamHI and HindIII enzyme sites. The recombinant shRNA vectors were named pshB7-H3 and pshNC, respectively. All vectors were confirmed by enzyme digestion and DNA sequencing analysis. The constructed vectors were then transfected into HeLa cells using Lipofectamine TM 2000 (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer's instructions and screened using 800 lgÁmL À1 of G418 (Invitrogen).
ScFv construction, retrovirus package and cell infection
Total RNA was extracted from hybridoma cells secreting antibody against B7-H3 using TRIzol reagent (Takara Biotechnology, Tokyo, Japan) in accordance with the manufacturer's instructions. Then, 1 lg of RNA was used for cDNA synthesis in conjunction with Primerscript Reverse Transcriptase (TaKaRa Biotechnology) in a two-step procedure. Variable domains of light and heavy chains, respectively, were amplified from cDNA using two sets of degenerate primers (see Tables S2 and S3 ) and Taq DNA polymerase (Dingguo Changsheng, Beijing, China). After verification by DNA sequencing analysis, variable heavy (VH) and variable light (VL) chains with the removal of secretory signal, respectively, were amplified by specific primers (see Table S4 ) with embedded restriction sites, MluI 
RT-PCR and quantitative PCR analysis
Total RNA was extracted using TRIzol reagent (Takara Biotechnology). Accordingly, 1 lg of RNA was used for cDNA synthesis in conjunction with a Primerscript RT Kit (Takara Biotechnology) to amplify B7-H3 or VH, VL and the anti-B7-H3 ScFv gene. b-actin was used as a loading control. The primer sequences are presented in the Table S4 . Products from RT-PCR were electrophoresed via a 1.2% agarose gel with ethidium bromide and signals were quantified by densitometric analysis using the Multilmage Light Cabinet (Alpha Innotech, San Leandro, CA, USA). The mRNA quantitative alteration of c-Myc and LDHA was evaluated by quantitative PCR using an ABI 7500 Real-Time RT-PCR system (Applied Biosystems, Foster City, CA, USA) and SYBR Premix Ex TaqII in accordance with the manufacturer's instructions (Takara Biotechnology). Primer sequences are also shown in the Table S4 . Data were standardized with b-actin to control variability in expression levels.
Western blot analysis
Samples were obtained by cell lysis in Ripa buffer and centrifugation. The protein concentrations were quantified using the BCA protein assay kit (Dingguo Changsheng). Next, 50 lg of protein from each sample was separated by SDS/ PAGE. The primary antibodies used in this experiment were antibodies against Fab (Sigma-Aldrich, St Louis, MO, USA), B7-H3 (Abcam, Cambridge, UK), ENO1 (Novusbio, Littleton, CO, USA), c-Myc (Abcam) and LDHA (Abcam) at a dilution of 1 : 1000. Goat anti-mouse, goat anti-rabbit and rabbit anti-goat IgG coupled to horseradish peroxidase (ZSBG Biological Technology) were used as secondary antibodies at a dilution of 1 : 5000. b-actin (ZSBG Biological Technology) was used as an internal standard.
CCK-8 assay
Samples were seeded into five 96-well culture plates (Corning, New York, NY, USA) at 2 9 10 3 per well. D 450 was monitored using a Epoch microplate spectrophotometer (BioTek Inc., Winooski, VT, USA) with the reagent of the CCK8 kit (KeyGen Biotech, Nanjing, China) being added to the samples after cultivation for 0, 24, 48, 72 and 96 h. The proliferation curve of each group was plotted on the basis of the absorption values.
Colony formation assay 2.0 9 10 2 cells were plated on culture dishes (diameter 100 mm). After 14 days, cells were fixed with methanol and stained with 0.1% crystal violet. Visible colonies were counted manually.
Scratch wound assay
Cells were seeded into six-well plates and grown until approximately 90% confluence and then FBS was retracted. After 12 h, a linear wound was created in the confluent monolayer using a pipette tip. The wounded monolayer was washed to remove cell debris and wounds were then photographed at 0 and 48 h. The difference between the width of wounds at 0 and 48 h represents the migration distance of cells.
Transwell invasion assay
Matrigel (Corning) was prepared in accordance with the manufacturer's instructions. Samples were trypsinized and resuspended in serum-free DMEM. 5 9 10 4 cells were seeded into the upper part of the chamber and cultured for 48 h and then 600 lL of DMEM with 10% FBS as an attractant was added to the lower compartment. The traversed cells were fixed with 95% ethyl alcohol for 5 min and stained with 0.2% crystal violet for 10 min and observed using an inverted microscope. The results are presented as a sum of the number of traversed cells in five random high power fields.
Pull-down assay, LC-MS and immunoprecipation
HeLa cells were cultured until approximately 80% confluence in culture dishes (diameter 100 mm) and lysed in 1 mL of ice-cold Ripa lysis buffer at 4°C for 45 min using a plate shaker at 300 rpm. The product was collected by centrifugation at 14 000 g for 15 min and then incubated with 20 lL of Protein-A/G PLUS-Agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) with gentle mixing for 4 h at 4°C. Supernatants were collected with the removal of Protein-A/G PLUS-Agarose and divided equally. Next, 5 lg of rabbit antibody against B7-H3 (Abcam) and normal rabbit IgG as a control (Santa Cruz Biotechnology), respectively, were added to 500 lL of the supernatants for 24 h at 4°C and sequentially incubated with 20 lL of Protein-A/G PLUS-Agarose again overnight.
Immunoprecipitates were collected by centrifugation at 2000 g for 3 min and subjected to SDS/PAGE using 12% polyacrylamide gel. The approximately 50 kDa band of the treated and control groups was sent for LC-MS at the Beijing Proteome Research Center and Beijing BangFei Bioscience. According to the results of LC-MS, ENO1 was screened out (Table 2 ) and it was confirmed by immunoprecipation that the gel band at 50 kDa was detected by western blotting using mouse anti-human-ENO1 (Novusbio) as a primary antibody at a dilution of 1 : 1000.
ENO1 human activity assay
The samples were prepared using an ENO1 human activity assay kit in accordance with the manufacturer's instructions of (Abcam). Accordingly, 10 lg of each sample was added to the wells of a microplate coated with antibody against ENO1 and incubated for 2 h at room temperature. After incubation, each well was aspirated and washed twice, sequentially, with 200 lL of activity solution (i.e. the substrate of ENO1) being gently added to the incubated wells. D 340 for each well was recorded as a kinetic reading at intervals of 1 min for 60 min, with the decay rate representing the activity of ENO1.
Enhanced ATP assay
The samples were prepared in accordance with the protocol provided with the Enhanced ATP assay kit (Beyotime, Shanghai, China). Accordingly, 20 lL of supernatant of each sample was added to 100 lL of ATP detection solution and then the relative light unit (RLU) values were recorded using a Glomax 20/20 luminometer (Promega, Madison, WI, USA). A standard curve was protracted from the RLU values of ATP at concentrations of 0, 0.01, 0.05, 0.1, 0.5, 1, 5 and 10 nmolÁL
À1
. The results were standardized by the protein concentration of each sample, finally presented as ATP/protein (nmolÁmg
).
Lactic acid assay
The cells were cracked by ultrasound and the lactic acid assay was performed in accordance with the manufacturer's instructions (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). D 530 was monitored using an ultraviolet spectrophotometer. A standard curve was protracted with respect to lactate at concentrations of 0, 0.3, 0.5, 1, 1.5, 2, 2.5 and 3 mmolÁL
À1
. The data were standardized by the protein concentration of each sample.
Statistical analysis
All statistical analyses were performed using SPSS, version 16.0 (SPSS Inc., Chicago, IL, USA). A chi-square test was performed to analysis the result of IHC; One-way analysis of variance (ANOVA) was performed to allow comparisons among each group; Dunnett's t-test was performed to analysis the comparison between treated groups and the control group. Data were expressed as the mean AE SEM. P < 0.05 (two-tailed) was considered statistically significant.
Results
The expression level of B7-H3 was positively correlated with clinical features of CCT specimens First, IHC was performed on tissue arrays, including 58 paraffn-embedded CCT specimens and 16 normal cervical tissues, aiming to investigate the expression level of B7-H3 in CCT specimens. The results showed that 46 of 58 (79.3%) CCT specimens showed positive staining of B7-H3. The 46 positive specimens were divided into those showing high expression and low expression ( Fig. 1) and subsequent statistical analysis (Table 1 ) revealed significant differences between the expression level of B7-H3 and the degree of differentiation (P = 0.016), clinical stage (P = 0.035) and T status (P = 0.031) of the CCT specimens. However, there were no statistical differences between the expression level of B7-H3 and age (P = 0.752), as well as lymph node metastasis (P = 0.165). The results demonstrate that the expression level of B7-H3 was positively correlated with the degree of differentiation, clinical stage and T status of CCT specimens.
Cell models constructed with targeted-B7-H3 shRNA and intracellular anti-B7-H3 ScFv Furthermore, pshB7-H3 was constructed and tranfected into HeLa cells to establish a cell model with decreased expression of B7-H3, named HeLa/pshB7-H3. The pshNC was used to establish the control group, named HeLa/pshNC. As shown in Fig. 2A,B , both the mRNA and protein expression levels of B7-H3 in HeLa/pshB7-H3 were significantly reduced compared to the wild-type (WT) group detected by RT-PCR and western blotting, and the protein level decreased by 51.31%, as shown in Fig. 2C (P < 0.01), although, in HeLa/pshNC cells, no obvious differences was observed (P > 0.05). These results indicate that pshB7-H3 could effectively downregulate the expression of B7-H3 in HeLa cells.
Meanwhile, the hybridoma cells secreting monoclonal antibody against B7-H3, as previously established in our laboratory, were used to construct a retroviral expression system bearing anti-B7-H3 ScFv gene. Then, the vector was transduced into HeLa cells to block the function of B7-H3, named HeLa/anti-B7-H3, and the empty pSLX-CMV vector was applied to establish the mock group, named HeLa/pSLX-CMV. As shown in Fig. 2D ,E, VH (384 bp), VL (378 bp) and ScFv (807 bp) could be transcribed into mRNA normally, and they also showed a high level of expression. Furthermore, the mRNA of ScFv could be translated into protein (approximately 35 kDa) successfully in HeLa cells, whereas the mRNA and protein levels of B7-H3 showed no obvious difference in HeLa cells (P > 0.05; Fig. 2F-H) . These data demonstrated that anti-B7-H3 ScFv could be expressed by HeLa cells without affecting B7-H3 protein expression.
The inhibition of B7-H3 attenuated the malignancy of HeLa cells
A CCK-8 assay was performed on the cell models to investigate the effect of pshB7-H3 and anti-B7-H3 ScFv on the proliferation of HeLa cells in vitro. As shown in Fig. 3A , the proliferation of HeLa/pshB7-H3 and HeLa/anti-B7-H3 cells was inhibited in a timedependent manner and there was obvious inhibition of the former after 24 h, whereas inhibition for the latter occurred after 72 h (P < 0.01). Furthermore, a colony formation assay was performed (Fig. 3B,C) . As the results indicated, the number of colonies in the HeLa/ pshB7-H3 cell groups (120.3 AE 5.24) was significantly decreased (P < 0.01) compared to the WT and NC groups (215.3 AE 10.91 and 206.3 AE 11.62, respectively) and HeLa/anti-B7-H3 (89.3 AE 3.93) showed a similar tendency compared to the WT and mock groups (228.3 AE 11.53 and 235.3 AE 13.59, respectively). These results suggested B7-H3 might involve in the proliferation of cervical cancer cells.
To explore the migration ability in vitro, we conducted a scratch wound assay on the constructed models. Representative wound healing images (0 and 48 h) and statistical analysis are shown in Fig. 3D ,E (P < 0.01). As the results indicated, the downregulated expression of B7-H3 by pshB7-H3 in HeLa cells resulted in a markedly decreased migration ability compared to the WT and NC groups. Similarly, HeLa/anti-B7-H3 also showed an inhibited migratory speed. The migration distance of HeLa/pshB7-H3 and HeLa/anti-B7-H3 was significantly reduced by 45.2% and 60.8%, respectively (P < 0.01). These data demonstrate that B7-H3 might play an important role in regulating the migratory ability of cervical cancer cells. We further investigated the effect of B7-H3 on the ability of invasion in HeLa cells by a transwell invasion assay and representative images of traversed cells and the statistical analysis are shown in Fig. 3F , G (P < 0.01). The traversed cell numbers of HeLa/ pshB7-H3 were significantly reduced by 61.1% and 63.8% compared to the WT and NC groups, respectively (P < 0.01). Similarly, HeLa/anti-B7-H3 was significantly reduced by 73.7% and 72.5% compared to the WT and mock groups (P < 0.01). These experimental data confirmed that B7-H3 might be able to enhance the invasion ability of cervical cancer.
B7-H3 directly interacted with ENO1 and altered its activity in HeLa cells
A pull-down assay was carried out to analyze the protein directly interacting with B7-H3 in HeLa cells and further investigate the mechanism of B7-H3 in tumorgenesis, with the samples separated by SDS-PAGE being identified by LC-MS. As a result of the difference between treated and control groups, several potential proteins (Table 2) were screened out according to their scores from high to low. Finally, ENO1 was identified as the target protein, as subsequently confirmed by immunoprecipitation in HeLa cells (Fig. 4A) . Next, the expression of ENO1 was detected by RT-PCR and western blotting. As shown in Fig. 4C ,D, no obvious differences in mRNA and protein expression were observed in either HeLa/pshB7-H3 or HeLa/anti-B7-H3. However, the activity of ENO1 was found to decrease both in HeLa/pshB7-H3 and HeLa/anti-B7-H3 using a human ENO1 assay kit. As shown in Fig. 4B , the plateau time of HeLa, HeLa/ pshNC and HeLa/pSLX-CMV was approximately 40 min, whereas the time for HeLa/pshB7-H3 and HeLa/anti-B7-H3 was almost 60 min, which suggested that the same consumption of substrate by ENO1 of HeLa/pshB7-H3 and HeLa/anti-B7-H3 took longer. Taken together, we consider that B7-H3 interacted with ENO1 by altering its activity rather than by affecting its expression in HeLa cells.
Silencing or blocking B7-H3 affected the glycolysis of HeLa cells
ENO1 functions as an important glycolysis enzyme and, theoretically, the downregulation of ENO1 activity would affect the level of the products of glycolysis. Therefore, the production of ATP and lactate in HeLa/pshB7-H3 and HeLa/anti-B7-H3 was detected using a lactate and ATP assay kit (Fig. 5) . ATP and lactate in HeLa/pshB7-H3 cells were significantly reduced by 37.7% and 39.3%, as well as by 42.1% and 43.6%, respectively, compared to the WT and NC groups (P < 0.01) and HeLa/anti-B7-H3 was reduced by 36.6% and 34.9%, as well as by 34.2% and 35.9%, respectively, compared to the WT and mock groups (P < 0.05). These glycolysis alterations of the treated groups could be considered as evidence for the interaction between B7-H3 and ENO1. c-Myc and LDHA confirmed the alteration of glycolysis at the molecular level
For further confirmation of the alteration of glycolysis at the molecular level, the expression of some glycolysis-related molecules was detected by a quantitative PCR and western blotting, and obvious differences were observed in c-Myc and LDHA (P < 0.01; Fig. 6 ). The mRNA and protein level of cMyc and LDHA in HeLa/pshB7-H3 was significantly reduced compared to HeLa and HeLa/pshNC, with c-Myc and LDHA in HeLa/anti-B7-H3 showing a similar reduction. These results suggest that the c-Myc-LDHA axis might comprise the downstream effective pathway.
Discussion
B7-H3 is multifunctional but also noted for its dual role in immunoregulation and tumorigenesis compared to other immune checkpoints [13] [14] [15] . On the one hand, the role of B7-H3 in the tumor immunoregulation remains inconclusive; on the other, the function of B7-H3 and its downstream molecule in the proliferation and progression of tumor is incomplete. In the present study, IHC was performed on a tissue array, with the results obtained indicating that 79.3% of CCT specimens stained positively for B7-H3. The statistical analysis (Table 1) showed the expression level of B7-H3 was positively correlated with the degree of differentiation, clinical stage and T status of showed that the protein level of B7-H3 was not changed. b-actin was used as a loading control. The statistical analysis of (H) is shown using one-way ANOVA.
CCT specimens, whereas it was not correlated with the age of patients and lymph node metastasis. However, the results are different from some studies that have considered the expression of B7-H3 to be positively correlated with lymph node metastasis [16] . We consider that there are two possible explanations for this. First, different origins of cancers may tend to rely on different metastasis approaches; second, a lack of samples with lymph node metastasis may lead to different statistical results, and so the sample volume should be enlarged to further improve any analysis of the correlation [16] .
Furthermore, two different vectors [targeted B7-H3 shRNA to downregulate its expression ( Fig. 2A,B) and intracellular anti-B7-H3 ScFv to block its function (Fig. 2D,E) ] were constructed. We also attempted to explore the mechanism of B7-H3 in tumorgenesis by employing these two types of technology, at the same time aiming to develop the intracellular anti-B7-H3 ScFv into a therapeutic intrabody for oncotherapy Fig. 3 . The malignancy of HeLa cells weakened when B7-H3 was inhibited. (A) A CCK-8 assay was applied to investigate the proliferation of cell models and the curve of each group was plotted on the basis of attenuance values at 0, 24, 48, 72 and 96 h, from which the obvious inhibitory proliferation of HeLa/pshNC and HeLa/anti-B7-H3 was observed after 24 and 72 h, respectively. **P < 0.01. (B) Representative colony formation assay images at 14 days. The colony numbers of HeLa/pshB7-H3 and HeLa/anti-B7-H3 were significantly fewer than for cells without treatment. (C) The statistical analysis of (B) using one-way ANOVA. **P < 0.01. (D) Representative wound healing images at 0 and 48 h. The results showed that the migration distance of HeLa/pshB7-H3 and HeLa/anti-B7-H3 was less than for cells without treatment (scale bars = 100 lm). (E) The statistical analysis of (D) is shown using one-way ANOVA. **P < 0.01. (F) Representative transwell invasion images at 48 h. The results are counts of the total cell number of five random high power fields (scale bars = 100 lm). The traversed cells of HeLa/pshB7-H3 and HeLa/anti-B7-H3 were significantly decreased compared to cells without treatment. (G) The statistical analysis of (F) is shown using one-way ANOVA. **P < 0.01. Scale bar = 1000 lm.
( Fig. 7) . Based on HeLa cell models constructed by B7-H3 shRNA vectors or anti-B7-H3 ScFv virus, a panel of cell behavior assays was performed. The results obtained demonstrate that both decreasing the expression and blocking the function of B7-H3 could inhibit cell proliferation (Fig. 3A,B) and weaken the ability of migration and invasion (Fig. 3D,F) , which suggests that B7-H3 might be a key target in attenuating tumor malignancy.
Based on the above results, pull-down and LC-MS experiments were carried out aiming to identify the downstream molecule assisting B7-H3 in tumorgenesis, with ENO1, an important enzyme in glycolysis, being identified as a potential protein (Fig. 4A and Table 2 ). This finding is consistent with previous studies reporting that B7-H3 could affect the glycolysis of cancer cells [8, 15] . Through a literature review, we found that B7-H3 and ENO1 had many similarities in tumors. For example, both of them are reported to be overexpressed in many kinds of cancers and to promote tumor proliferation and invasion; moreover, they could share a common signal pathway (PI3K/Akt pathway) to influence tumor glycolysis [8, 12, 16, 17] . Interestingly, several recent studies suggested that ENO1 might be involved in immunoregulation and trigger a strong specific humoral and cellular immune response, which in turn comprises corroborative evidence suggesting that ENO1 might interact with B7-H3 [18, 19] . Subsequently, the expression and activity of ENO1 were detected in the cell models. The activity of ENO1 was found to be changed, whereas its expression was not. The results indicated that B7-H3 might influence the activity of ENO1 without altering its expression (Fig. 4B-D) .
Because ENO1 plays an important role in tumor glycolysis, the levels of lactate and ATP were evaluated in constructed models, which showed that the levels of both lactate and ATP were reduced when either B7-H3 expression was downregulated or function was blocked (Fig. 5) . Lactate, a final metabolite of glycolysis, has long been considered as an essential factor in tumor progression. The acidic extracellular microenvironment resulting from its accumulation could benefit the metastasis, angiogenesis and chemoresistance of a tumor [20, 21] . Surprisingly, two recent studies have demonstrated that lactate, once considered as a metabolic waste, can be recycled by cancer cells as a fuel to produce energy [22, 23] . In general, tumor cells need more energy (i.e. ATP) than normal tissue not only for survival, but also for proliferation and metastasis; thus, strategies aimed at reducing ATP have been exploited as a type of antitumor therapy [24] . Therefore, the decreased levels of lactate and ATP attenuating tumor malignancy are accordance with our results with respect to cell behavior assays. For further investigation of this phenomenon, the expression of some glycolysis-related genes was detected by quantitative PCR and western blotting with the cell models. c-Myc and LDHA were found to show lower expression levels, which confirmed the role of B7-H3 in tumor glycolysis at a molecule level (Fig. 6) . However, the functional forms of c-Myc and LDHA still remain unknown, with three possibilities existing. First, c-Myc and LDHA may be the direct downstream pathway of B7-H3; second, these two molecules, as important factors in the glycolysis-related signal pathway, may be affected by the alteration of ENO1 caused by B7-H3 fuction; and, third, c-Myc/LDHA might be the downstream effective pathway of the interaction between B7-H3 and ENO1, mediating the Warburg effect to promote tumor progression [25] .
Noticeably, in the present study, intracellular anti-B7-H3 ScFv was shown to be as effective as targeted B7-H3 shRNA in terms of anti-tumor function. Moreover, as a minimized intrabody, it is distinct from the antibody against membranal B7-H3, which could impair tumor glycolysis and weaken malignancy by precisely inhibiting intracellular B7-H3. Considering that side effects of targeted-metabolism strategies are still inevitable as a result of the same metabolic enzymes that are shared between tumor and normal cells, B7-H3, as an overexpressed oncoprotein, may be a promising target for anti-metabolism oncotherapy [24] . Importantly, it has already been demonstrated The level of ATP was detected in each group and Dunnett's t-test was used as the statistical analysis. The production of ATP in HeLa/pshB7-H3 and HeLa/anti-B7-H3 was significantly reduced compared to cells without treatment. *P < 0.05; **P < 0.01. (B) The level of lactate was evaluated in each group and Dunnett's ttest was employed for the statistical analysis. The production of lactate in HeLa/pshB7-H3 and Hela/B7-H3-ScF was significantly less than for cells without treatment. **P < 0.01.
that a high level of lactate secreted into the tumor microenvironment by cancer cells will exert an inhibitory influence on either the innate or adaptive immune response against a tumor [26] . Therefore, we hypothesized that the inhibitory role of B7-H3 in tumor immunoregulation could be partly implemented with the assistance of the lactate produced by tumor cells, which represents an avenue for further research in our subsequent studies. In summary, the present study contributes to enriching the theory of B7-H3 concerning tumor glycolysis, providing evidence of B7-H3 comprising a valuable oncotarget and also presenting a new idea for anti-B7-H3 cancer therapy. 
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